权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MIXED CHIMERISM AND TOLERANCE IN CYNOMOLGUS MONKEYS

食蟹猴的混合嵌合和耐受

基本信息

批准号：
6129890
负责人：
TATSUO KAWAI
金额：
$ 23.17万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
1995
资助国家：
美国
起止时间：
1995-03-15 至 2001-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6129890
关键词：
Macaca fascicularis T lymphocyte artificial immunosuppression bone marrow transplantation disease /disorder model immune tolerance /unresponsiveness kidney transplantation mixed lymphocyte reaction test monoclonal antibody nonhuman therapy evaluation technology /technique development thymus tissue mosaicism transplantation immunology whole body irradiation dosage

项目摘要

The induction of specific transplantation tolerance, which might eliminate both the need for long-term immunosuppressive medications and the persistent problem of chronic rejection, remains a major goal of clinical organ transplantation. Previous studies from our laboratory have demonstrated that the establishment of mixed lymphohematopoietic chimerism provides an effective means for the induction of long-term transplantation tolerance across major histocompatibility barriers in mice. Based on these murine studies, we successfully developed a non-myeloablative preparative regimen that permits the induction of mixed chimerism and renal allograft tolerance following bone marrow transplantation in MHC-mismatched cynomolgus monkeys, without GvHD. However, to apply this regimen to a clinical setting, several modifications will be necessary. Therefore, the major goals of this proposal are to achieve consistent tolerance, to reduce further the morbidity of the preparative regimen, and to extend its use to the transplantation of cadaveric organs. Specifically, we will: 1) evaluate the addition of costimulatory blockade (with anti-CD40L monoclonal antibody and/or CTLA4-Ig) to the preparative regimen; 2) attempt to minimize the radiation requirements of the preparative regimen by utilizing high-dose mobilized peripheral blood stem cells (PBSC) for the induction of mixed chimerism; and 3) modify the preparative regimen to improve its applicability to cadaver-donor transplantation in humans. In addition, we will investigate and compare the underlying mechanism of tolerance induced by each of these non-myeloablative regimens, with particular emphasis on distinguishing central from peripheral mechanisms. These analyses should provide valuable information for extending this approach to clinical allotransplantation.

诱导特异性移植耐受，这可能消除对长期免疫抑制药物的需要和慢性排斥反应的持续问题，仍然是临床器官移植的主要目标。本实验室以前的研究表明，混合淋巴造血嵌合体的建立为诱导小鼠跨越主要组织相容性障碍的长期移植耐受提供了一种有效的手段。基于这些鼠研究，我们成功地开发了一种非清髓性制备方案，其允许在MHC不匹配的食蟹猴中骨髓移植后诱导混合嵌合体和肾同种异体移植物耐受，而没有GvHD。然而，为了将该方案应用于临床环境，需要进行几次修改。因此，该建议的主要目标是实现一致的耐受性，以进一步降低准备方案的发病率，并将其应用扩展到尸体器官的移植。具体而言，我们将：1）评估向制备方案中加入共刺激阻断（用抗-CD 40 L单克隆抗体和/或CTLA 4-IG）; 2）通过利用高剂量动员的外周血干细胞（PBSC）诱导混合嵌合体，尝试使制备方案的辐射要求最小化;和3）修改制备方案以改善其对人体尸体供体移植的适用性。此外，我们将研究和比较这些非清髓性方案诱导耐受的潜在机制，特别强调区分中枢和外周机制。这些分析将为临床同种异体移植提供有价值的信息。